Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-08-23 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司2023年半年度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年半年度报告" which translates to "2023 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, company overview, R&D progress, financial indicators, and other substantive financial and operational information for the period January 1, 2023 to June 30, 2023. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes actual financial statements and detailed analysis, which fits the definition of an Interim / Quarterly Report (IR). It is not a mere announcement or certification, nor is it a full annual report (10-K). Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-08-23 Chinese
长春百克生物科技股份公司第五届监事会第十三次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the 5th Supervisory Board of Changchun Baike Biotechnology Co., Ltd. It includes approvals of the 2023 semi-annual report, special reports on the use of raised funds, project delays, stock incentive plans, and other supervisory board decisions. The document references the 2023 semi-annual report and related announcements but does not contain the actual financial statements or substantive financial data itself. The document length is 3323 characters, which is relatively short and mainly serves as an official announcement of supervisory board meeting resolutions and approvals. It also repeatedly directs readers to the Shanghai Stock Exchange website for the full reports and detailed disclosures. Therefore, this document is not the semi-annual report itself (which would be an Interim/Quarterly Report - IR), but rather an official announcement of supervisory board resolutions related to the semi-annual report and other matters. This fits best with the Regulatory Filings (RNS) category, which covers general regulatory announcements and compliance documents that do not fit other specific categories. Hence, the classification is RNS with high confidence.
2023-08-23 Chinese
长春百克生物科技股份公司关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 half-year performance explanation meeting (业绩说明会) for Changchun Baike Biotechnology Co., Ltd. It specifies the date, time, location, and participation method for the meeting, which is intended to discuss the company's 2023 half-year operating results and financial indicators. The document does not contain actual financial statements or detailed financial analysis but rather serves as a notice for an upcoming investor presentation event. According to the classification rules, such announcements about meetings or presentations are classified as Investor Presentation (IP) if they contain detailed presentation content, or as Regulatory Filings (RNS) if they are just announcements. However, since this document is specifically about an investor meeting to explain half-year results and includes details on how investors can participate and ask questions, it aligns best with the Investor Presentation (IP) category, which covers detailed presentations for investors focusing on financials, strategy, and market position. The document length is short and it does not contain the actual report, so it is not an Interim/Quarterly Report (IR) or Annual Report (10-K). Therefore, the best fit is Investor Presentation (IP).
2023-08-15 Chinese
长春百克生物科技股份公司2023年半年度业绩预告的自愿性披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement of the company's 2023 half-year performance forecast, including estimated net profit and revenue for the period January 1 to June 30, 2023. It explicitly states that the data is preliminary, unaudited, and that the final accurate financial data will be disclosed in the formal 2023 half-year report. The document is short (1070 characters) and serves as a performance forecast announcement rather than a full interim or quarterly report containing actual financial statements or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an announcement of forecasted results, not the actual interim report itself.
2023-07-10 Chinese
长春百克生物科技股份公司第五届董事会独立董事关于第五届董事会第十七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Changchun Baike Biotechnology Co., Ltd. regarding a board meeting decision on adjusting the restricted stock incentive plan's grant price. It references compliance with company law, stock exchange listing rules, and internal governance documents. The content is a formal opinion on a board matter, not a full report, financial statement, or announcement of voting results. It is related to board/management information about decisions made at a board meeting. The document length is short and focused on the independent directors' opinion, fitting the category of Board/Management Information (MANG).
2023-06-27 Chinese
长春百克生物科技股份公司第五届董事会第十七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 17th meeting of the 5th Board of Directors of Changchun Baike Biotechnology Co., Ltd. It details the board meeting date, attendance, and voting results on investment and stock incentive plan adjustments. It does not contain financial statements or detailed financial performance data. It is a formal disclosure of board decisions, including investment and stock incentive plan changes, which fits the category of Board/Management Information (MANG). The document length is short (1385 characters), and it is not a report or presentation but an official announcement of board resolutions.
2023-06-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.